Abbott Labs (NYSE:ABT) is set to report its Q2 2018 earnings on July 18, and we expect the company to post steady growth, led by its Diagnostics and Generic Pharmaceuticals segments. While the Diagnostics business will continue to benefit from Alere acquisition synergies, Generic Pharmaceuticals...
Abbott Labs (NYSE:ABT) is set to report its Q2 2018 earnings on July 18, and we expect the company to post steady growth, led by its Diagnostics and Generic Pharmaceuticals segments. While the Diagnostics business will continue to benefit from Alere acquisition synergies, Generic Pharmaceuticals...
Share this Article
Recommended